# EDGAR Filing Document

**Accession Number:** 0001386570
**File Stem:** 0001213900-25-073647
**Filing Date:** 2025-8
**Character Count:** 21793
**Document Hash:** 51bb8cb9734e3b9a6bc22f34623bf313
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-073647.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001213900-25-073647

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**EFFECTIVENESS DATE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Niagen Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001386570
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262940963
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289417
- **FILM NUMBER:** 251198372

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024
- **BUSINESS PHONE:** 310-388-6706

**MAIL ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ChromaDex Corp.
- **DATE OF NAME CHANGE:** 20080624

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CODY RESOURCES, INC.
- **DATE OF NAME CHANGE:** 20070112

**As filed with the Securities and Exchange Commission on August 8, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8** 

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**NIAGEN BIOSCIENCE, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **26-2940963** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**10900 Wilshire Blvd., Suite 600**

**Los Angeles, California 90024**

**(310) 388-6706**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Niagen Bioscience, Inc. 2017 Equity Incentive Plan**

(Full title of the plan)

Robert Fried

Chief Executive Officer

10900 Wilshire Blvd., Suite 600

Los Angeles, California 90024

(310) 388-6706

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copies to:*

 

Ben Orlanski, Esq. Louis Rambo, Esq. Proskauer Rose LLP 2029 Century Park East, Suite 2400 Los Angeles, CA 90067 (310) 557-2900 Ozan Pamir Chief Financial Officer 10900 Wilshire Boulevard, Suite 600 Los Angeles, CA 90024 (310) 388-6706

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is filed pursuant to General Instruction E to Form S-8 by Niagen Bioscience, Inc. (the "Company") for the purpose of registering an additional 4,750,000 shares of the Company's common stock, par value $0.001 per share ("common stock"), that were added to the Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended (the "2017 Plan"), pursuant to a share reserve increase approved by the Company's stockholders on June 24, 2025. The Company previously registered shares of its common stock for issuance under the 2017 Plan on Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "SEC") on October 31, 2017 (File No. 333-221246), March 23, 2018 (File No. 333-223889), August 22, 2018 (File No. 333-226972), August 18, 2020 (File No. 333-248104) and June 22, 2023 (File N0. 333-272830) (the "Prior Registration Statements"). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

---

| | |
|:---|:---|
| **ITEM 3.** | **INCORPORATION OF DOCUMENTS BY REFERENCE** |

---

The following documents filed by the Company with the SEC are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) The Company's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1386570/000162828025009774/cdxc-20241231.htm) for the fiscal year ended December 31, 2024, filed with the SEC on March 4, 2025 (including the portions of the Company's
definitive proxy statement on [Schedule 14A](http://www.sec.gov/Archives/edgar/data/1386570/000162828025020690/cdxc-20250429.htm) filed on April 29, 2025 incorporated by reference therein);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) The Company's Quarterly Reports on [Form 10-Q](http://www.sec.gov/Archives/edgar/data/1386570/000162828025023127/cdcx-20250331.htm) for the quarterly period ended March 31, 2025, filed with the SEC on May 7, 2025, and for the quarterly period ended June 30,
2025, filed with the SEC on August 6, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) The Company's Current Reports on Form 8-K filed with
the SEC on [February 27, 2025](http://www.sec.gov/Archives/edgar/data/1386570/000162828025008691/cdxc-20250225.htm) , [March 19, 2025](http://www.sec.gov/Archives/edgar/data/1386570/000162828025013681/cdxc-20250317.htm) , [June 27, 2025](http://www.sec.gov/Archives/edgar/data/1386570/000162828025033302/cdxc-20250624.htm) , and [July 29, 2025](http://www.sec.gov/Archives/edgar/data/1386570/000162828025036445/cdxc-20250725.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) The description of the Company's common stock included
in the Company's [Form 8-A](http://www.sec.gov/Archives/edgar/data/1386570/000141588916005586/cdxc8a_apr212016.htm) filed with the SEC on April 21, 2016, including any amendments or reports filed for the purpose of updating such description.

In addition, all of the Company's reports filed with the SEC pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, other than current reports furnished under Item 2.02 and Item 7.01 of Form 8-K and any exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to filing a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such reports.

Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

---

| | |
|:---|:---|
| **ITEM 8.** | **EXHIBITS.** |

---

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference from, and filed as Exhibit 3.1 to the Registrant's Annual Report on Form 10-K (File No. 001-37752) filed with the SEC on March 15, 2018).](http://www.sec.gov/Archives/edgar/data/1386570/000165495418002621/ex3-1.htm) |
| 4.2 | [Certificate of Amendment to the Certificate of Incorporation of the Registrant (incorporated by reference from, and filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37752) filed with the SEC on April 12, 2016).](https://www.sec.gov/Archives/edgar/data/1386570/000141588916005494/ex3-1.htm) |
| 4.3 | [Certificate of Amendment to the Certificate of Incorporation of the Registrant (incorporated by reference from, and filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-37752) filed with the SEC on March 19, 2025).](http://www.sec.gov/Archives/edgar/data/1386570/000162828025013681/niagenbioscienceinc-deam.htm) |
| 4.4 | [Amended and Restated Bylaws of the Registrant (incorporated by reference from, and filed as Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-37752) filed with the SEC on March 19, 2025).](http://www.sec.gov/Archives/edgar/data/1386570/000162828025013681/ex32-niagenbioscienceincam.htm) |
| 5.1\* | [Opinion of Proskauer Rose LLP.](ea025141401ex5-1_niagen.htm) |
| 23.1\* | [Consent of Crowe LLP.](ea025141401ex23-1_niagen.htm) |
| 23.2\* | [Consent of Marcum LLP.](ea025141401ex23-2_niagen.htm) |
| 23.3\* | [Consent of Proskauer Rose LLP (included in Exhibit 5.1).](ea025141401ex5-1_niagen.htm) |
| 24.1\* | [Power of Attorney (contained on the signature page hereto).](#pa_001) |
| 99.1 | [Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended (incorporated by reference from, and filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-37752) filed with the SEC on June 27, 2025).](http://www.sec.gov/Archives/edgar/data/1386570/000162828025033302/nage-2017equityincentivepl.htm) |
| 107\* | [Filing Fee Table](ea025141401ex-fee_niagen.htm) |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on August 8, 2025.

---

| | |
|:---|:---|
| **NIAGEN BIOSCIENCE, INC.** | **NIAGEN BIOSCIENCE, INC.** |
| By: | /s/ Robert Fried |
|  | Robert Fried |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert Fried and Ozan Pamir, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ ROBERT FRIED | Chief Executive Officer and Director | August 8, 2025 |
| Robert Fried | (Principal Executive Officer) |  |
| /s/ OZAN PAMIR | Chief Financial Officer | August 8, 2025 |
| Ozan Pamir | (Principal Financial and Accounting Officer) |  |
| /s/ FRANK JAKSCH JR. | Chairman of the Board and Director | August 8, 2025 |
| Frank Jaksch Jr. |  |  |
| /s/ GARY NG | Director | August 8, 2025 |
| Gary Ng |  |  |
| /s/ STEVEN RUBIN | Director | August 8, 2025 |
| Steven Rubin |  |  |
| /s/ WENDY YU | Director | August 8, 2025 |
| Wendy Yu |  |  |
| /s/ KRISTIN PATRICK | Director | August 8, 2025 |
| Kristin Patrick |  |  |
| /s/ ANN COHEN | Director | August 8, 2025 |
| Ann Cohen |  |  |
| /s/ HAMED SHAHBAZI | Director | August 8, 2025 |
| Hamed Shahbazi |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](ex5-1_001.jpg) | Proskauer Rose LLP 2029 Century Park East, Suite 2400, Los Angeles, California 90067-3010 |

---

August 8, 2025

Niagen Bioscience, Inc.

10900 Wilshire Blvd., Suite 600

Los Angeles, California 90024

Ladies and Gentlemen:

We are acting as counsel to Niagen Bioscience, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the preparation and filing with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), of a registration statement on Form S-8 (the "<u>Registration Statement</u>"), relating to the registration of an additional 4,750,000 shares of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>"), that may be issued by the Company pursuant to the Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended (the "Plan"). The shares of Common Stock are to be issued by the Company upon grant, vesting or exercise of certain stock-based awards (the "<u>Awards</u>") to be granted pursuant to the Plan.

As such counsel, we have participated in the preparation of the Registration Statement and have examined originals or copies of such documents, corporate records and other instruments as we have deemed relevant, including, without limitation: (i) the Amended and Restated Certificate of Incorporation of the Company, as amended to date; (ii) the Amended and Restated Bylaws of the Company; (iii) certain resolutions of the Board of Directors of the Company relating to the authorization and issuance of the Awards and the shares of Common Stock; (iv) certain resolutions of the Company's stockholders relating to the adoption of the Plan; (v) the Plan; and (vii) the Registration Statement, together with the other exhibits filed as a part thereof and including any documents incorporated by reference therein.

We have made such examination of law as we have deemed necessary to express the opinion contained herein. As to matters of fact relevant to this opinion, we have relied upon, and assumed without independent verification, the accuracy of certificates of public officials and officers of the Company. We have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of documents submitted to us as originals, the conformity to the original documents of all documents submitted to us as certified, facsimile or photostatic copies, and the authenticity of the originals of such copies. We have also assumed that certificates representing the shares of Common Stock will have been properly signed by authorized officers of the Company or their agents.

Based upon the foregoing, and subject to the limitations, qualifications, exceptions and assumptions expressed herein, we are of the opinion, assuming no change in the applicable law or pertinent facts, that the shares of Common Stock have been duly authorized and, when and to the extent issued in accordance with the terms of the Plan and any applicable Award, including payment of the applicable exercise price therefor, will be validly issued, fully paid and non-assessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is based upon and expressly limited in all respects to the General Corporation Law of the State of Delaware, as in effect on the date hereof, and we do not purport to be experts on, or to express any opinion with respect to the applicability thereto, or to the effect, of the laws of any other jurisdiction or as to matters of local law or the laws of local governmental departments or agencies within the State of Delaware. The reference and limitation to the "General Corporation Law of the State of Delaware" includes all applicable Delaware statutory provisions of law and reported judicial decisions interpreting these laws.

This opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any other matters. This opinion is rendered as of the date hereof, and we disclaim any obligation to advise you of any changes in applicable law or any other facts, circumstances, events, developments or other matters that may come to our attention after the date hereof that may alter, affect or modify the opinion expressed herein.

![](ex5-1_001.jpg)

August 8, 2025

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement. In giving the foregoing consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Proskauer Rose LLP |

---

Boca Raton \| Boston \| Chicago \| Hong Kong \| London \| Los Angeles \| New Orleans \| New York \| Paris \| São Paulo \| Washington, D.C.

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Niagen Bioscience, Inc. (formerly ChromaDex Corporation) of our report dated March 4, 2025 on the consolidated balance sheet of Niagen Bioscience, Inc. as of December 31, 2024 and the consolidated statements of operations, stockholders' equity, and cash flows for the year ended December 31, 2024, appearing in the Annual Report on Form 10-K of Niagen Bioscience, Inc. for the year ended December 31, 2024.

/s/ Crowe LLP

Costa Mesa, California

August 8, 2025

## Exhibit 23.2

**Exhibit 23.2**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 6, 2024 with respect to the financial statements of ChromaDex Corporation for the year ended December 31, 2023 included in the Annual Report on Form 10-K.

/s/ Marcum llp

New York, NY

August 8, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**Niagen Bioscience, Inc.**

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* |
| Fees to be Paid | Equity | Common Stock, par value $0.001 per share(1) | (1) | Other | 4750000 | $8.98 | $42655000.00 | 0.0001531 | $6530.49 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $42655000.00 |  | 6530.49 |
| Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  | 0.00 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $6530.49 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock, par value $0.001 per share ("Common Stock") that become issuable under the Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended (the "2017 Plan"), by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. Represents shares that were added to the 2017 Plan pursuant to a share reserve increase approved by the Registrant's stockholders on June 24, 2025. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are based upon the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Capital Market on August 1, 2025, a date that is within five business days prior to the filing of this Registration Statement.